Cervicitis

Summary

Cervicitis (MONDO:0002345) is a disease (an umbrella term covering 5 Mondo subtypes) and 5 clinical trials. Top therapeutic interventions include doxycycline anhydrous, azithromycin, and cefixime. A subtype of cervix disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervicitis
Mondo ID	MONDO:0002345
MeSH	D002575
DOID	DOID:2568
ICD-10-CM	N72
ICD-11	1433247301
NCIT	C26716
SNOMED CT	37610005
UMLS	C0007860
MedGen	3338
Is cancer (heuristic)	no

Also known as: cervicitis · cervicitis (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of cervix disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › cervix disorder › cervicitis

Related subtypes (8): cervical polyp, hypertrophic elongation of cervix, cervix endometriosis, uterine cervix leukoplakia, cervical incompetence, cervical metaplasia, cervix erosion, uterine cervix neoplasm

Subtypes (5): acute cervicitis, chronic cervicitis, endocervicitis, gonococcal cervicitis, Trichomonas cervicitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Azithromycin	Approved (phase 4)
Metronidazole	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE4	1
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01661985	PHASE4	UNKNOWN	Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced
NCT01072136	PHASE3	TERMINATED	Empiric Therapy of Mucopurulent Cervicitis (MPC)
NCT05675293	EARLY_PHASE1	UNKNOWN	Cervicitis by Iontophoresis
NCT04809727	Not specified	COMPLETED	Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy
NCT05564299	Not specified	COMPLETED	Rapid Diagnostic Assay for Gonorrhea and Chlamydia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOXYCYCLINE ANHYDROUS	4	3
AZITHROMYCIN	4	1
CEFIXIME	4	1
LYMECYCLINE	4	1
CHEMBL4299381	0	1
CHEMBL4303727	0	1
17	0	1